港股異動 | 澳優(1717.HK)連續3日反彈 旗下愛益森品牌推出嬰幼兒益生菌產品
格隆匯9月29日丨日前創近3年新低價的澳優(1717.HK)3日累計反彈近15%,報7.46港元,總市值128億港元。
澳優旗下愛益森品牌將推出首款適用於嬰幼兒使用的益生菌產品愛益森小橙盒,標誌着澳優向嬰幼兒配方食品佈局大健康產業邁出新一步。目前計劃於今年10月推出小藍盒及小粉盒即食型乳酸菌,並於明年1月至3月推出藍帽子認證保健品及嬰幼兒滴劑益生菌,以強化品牌競爭力。
瑞銀此前預計在政府激勵計劃幫助下,未來幾年的新生兒數量將趨於穩定。管理層亦表示會在適當的時候考慮回購。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.